Tacrolimus-Resistant SARS-CoV-2-Specific T Cell Products to Prevent and Treat Severe COVID-19 in Immunosuppressed Patients

Scientists proposed adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, Tacrolimus, for optimized performance in the immunosuppressed patient.